About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 488 record(s)
Req # A-2020-000191
Adverse Reaction Reports (AERs). Report numbers: E2B_02243861, E2B_02243989, 000729717, E2B_02873236, 000721963, E2B_02985259.Organization: Health Canada
November 2020
Req # A-2020-000238
Adverse Reaction Reports (AERs) for TEMODAL. Report numbers: E2B_00290601, E2B_00309209, E2B_00327688, E2B_00424964, E2B_00321840, E2B_00515512, E2B_00646778.Organization: Health Canada
November 2020
Req # A-2020-000264
Adverse Reaction Reports (AERs) for ZOPICLONE. Report numbers: 00728096, 000269548, E2B_02723478, E2B_02764439, E2B_02764544, E2B_02780298, E2B_02791294.Organization: Health Canada
November 2020
Req # A-2020-000302
Adverse Reaction Reports (AERs). Report numbers: E2B_02117433, E2B_02222419, E2B_02244913, E2B_02262499, E2B_02325016, E2B_02342497, E2B_02345476, E2B_02351697, E2B_02396498, 000726087, 000726137.Organization: Health Canada
November 2020
Req # A-2020-000328
Adverse Reaction Reports (AERs) for Vyvanse. Report numbers: 000731357, 000733940, E2B_02973620, E2B_02969928, E2B_02969837, E2B_02969820, E2B_02963971, E2B_02963934, E2B_02963103, E2B_02963088, E2B_02941816, E2B_02921064.Organization: Health Canada
November 2020
Req # A-2020-000349
Adverse Reaction Reports (AERs) for CLOPIDOGREL BISULFATE. Report numbers: E2B_02661867, E2B_02677415, 729458.Organization: Health Canada
November 2020
Req # A-2020-000358
Adverse Reaction Reports (AERs) for LEFLUNOMIDE. Report numbers: E2B_02836359, E2B_02865727, E2B_02865885, E2B_02836441, E2B_02878692, E2B_02451441, E2B_02883657, E2B_02866159, E2B_02880293, E2B_02867503, E2B_02871984, E2B_00471514, E2B_02875200,…Organization: Health Canada
November 2020
Req # A-2020-000362
Adverse Reaction Reports (AERs) for RIFAMPICIN. Report numbers: 727731, E2B_02714659, E2B_02733268.Organization: Health Canada
November 2020
Req # A-2020-000363
Adverse Reaction Report (AER) for RAMIPRIL. Report number: E2B_02980549.Organization: Health Canada
November 2020
Req # A-2020-000409
Adverse Reaction Reports (AERs). Report numbers: E2B_03042685, E2B_03043235, E2B_03043502, E2B_03046113.Organization: Health Canada
November 2020